Nanoparticle Treatment Tested for Endometriosis

Researchers developed a targeted drug delivery method that reduced endometriosis lesions in mice.

Updated on Sept. 26, 2026 in Women’s Health

A close-up view of a clear liquid inside a laboratory beaker, representing medical research innovation. — Washington State University researchers have engineered a targeted nanoparticle-based treatment that has successfully reduced the size and quantity of endometriosis lesions in mice. AI Illustration. Upload story photo >

Live Poll

Should medical researchers prioritize repurposing existing approved drugs to treat incurable diseases?

Washington State University researchers have developed a nanoparticle-based treatment that successfully reduced lesion size and quantity in a mouse model of endometriosis. This finding offers a potential alternative to hormonal therapies for the 1-in-10 women affected by the condition globally.

Why it matters

Current hormonal treatments for endometriosis often carry risks of reduced fertility and decreased bone density. This new approach aims to provide an effective, targeted treatment that avoids those systemic side effects by delivering medicine directly to the disease site.

A preclinical study published in Advanced Healthcare Materials demonstrated that a single injection of a dendrimer nanoparticle carrying niclosamide significantly reduced endometriosis lesion progression in mice. This research provides a proof-of-concept for targeted delivery.

The players

Washington State University

A public research university where scientists are investigating new treatment delivery systems for chronic reproductive conditions.

The details

Researchers utilized a dendrimer molecule to bond with niclosamide, an existing drug used to treat intestinal tapeworms, which normally suffers from low solubility. The nanocarrier system is designed to deliver the medication directly to disease-specific immune cells at the site of the lesions. This targeting mechanism is intended to maximize therapeutic benefit while minimizing the exposure of healthy tissue to the drug.

September 21, 2026: Washington State University announced the research findings.

Health Landscape

This development represents a departure from the standard hormonal management of endometriosis, which has dominated treatment protocols for decades. By focusing on targeted, non-hormonal delivery, it aligns with broader trends in nanomedicine aimed at mitigating systemic side effects in chronic disease.

While this study shows promise in an animal model, it is a preliminary finding that has not yet been tested in human trials. If you are managing endometriosis, it is worth discussing the current limitations of hormonal options and standard care with your gynecologist.

The takeaway

Targeted nanotherapy may eventually offer a way to treat endometriosis without the fertility or bone density concerns associated with current hormone-based medications. Patients should continue to monitor updates on clinical trial progress through their primary care provider or specialist.